Cannabidiol or CBD is a non-intoxicating cannabinoid produced by certain types of Cannabis plants. CBD interacts with endocannabinoid receptors (CB2) that are broadly distributed throughout human tissues and organs, meaning CBD has tremendous therapeutic potential. CBD functions as antagonist of CB1/CB2 receptor agonists (Pertwee 2008).
Research supports the use of CBD as a potential therapeutic for a wide range of conditions, particularly when inflammation, pain, spasticity or seizures are involved. CBD also activates the limbic region of the brain, which may reduce muscular tension and overall anxiety (Greydanus et al. 2013).
Boulder Hemp uses a full spectrum, whole plant supercritical CO2 extraction method, meaning we produce solvent free CBD oils that contain not only CBD, but also low quantities of other naturally occurring phytochemicals. Interestingly research demonstrates that CBD delivered in whole plant extract is more effective at reducing pain and inflammation, compared to equal doses of purified CBD (Gallily et al. 2015).
Pertwee, R. G. (2008), The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153: 199–215. doi:10.1038/sj.bjp.0707442
Greydanus, D.E., Hawver, E.K., Greydanus, M.M. and Merrick, J. (2013) Marijuana: Current Concepts. Frontiers in Public Health, 1, 42. http://dx.doi.org/10.3389/fpubh.2013.00042
Gallily, R., Yekhtin, Z. and Hanuš, L.O. (2015) Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy, 6, 75‐85. (https://www.scirp.org/journal/PaperInformation.aspx?paperID=53912)
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease.